[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paroxysmal-supraventricular-tachycardia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paroxysmal-supraventricular-tachycardia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100640090","nasval-svt-nasal-swab-versus-modified-valsalva-for-supraventricular-tachycardia-100640090",false,"NCT07617077","NASVAL-SVT: Nasal Swab Versus Modified Valsalva for Supraventricular Tachycardia","A Randomized Controlled Trial Comparing Nasal Swab and Modified Valsalva Maneuver for the Treatment of Supraventricular Tachycardia","NASVAL-SVT","Inclusion Criteria:\n\n* Age 18 years or older\n* Electrocardiographically confirmed supraventricular tachycardia (SVT): narrow QRS complex (≤120 ms), regular rhythm, rapid ventricular rate, documented on 12-lead ECG or continuous cardiac monitoring\n* Hemodynamic stability, defined as ALL of the following simultaneously present:\n* Systolic blood pressure ≥90 mmHg\n* Diastolic blood pressure ≥60 mmHg\n* Alert and oriented mental status (GCS 15)\n* No signs of acute end-organ dysfunction\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Pregnancy (known or suspected)\n* Inability to confirm SVT diagnosis by ECG criteria\n* Delta wave or pre-excitation pattern on ECG (Wolff-Parkinson-White syndrome or asymptomatic pre-excitation) - due to risk of ventricular fibrillation with vagal maneuvers\n* Wide QRS tachycardia (QRS ≥120 ms) where ventricular tachycardia cannot be excluded\n* Absolute contraindication to modified Valsalva maneuver (inability to assume supine position or passive leg elevation)\n* Contraindication to nasal swab (nasal surgery within 30 days, active epistaxis, visible nasal polyp or mass)\n* Hemodynamic instability requiring immediate synchronized cardioversion\n* Prior enrollment in this study (re-presentation with SVT)\n* Refusal to participate","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Supraventricular tachycardia (SVT) is a common heart rhythm disorder seen in emergency departments, causing a rapid heartbeat (typically 150-250 beats per minute). The current best non-drug treatment, the modified Valsalva maneuver (mVM), successfully restores normal rhythm in about 43% of cases. When these maneuvers fail, intravenous adenosine is used, which, while effective, can cause brief but distressing side effects such as chest tightness, shortness of breath, and intense anxiety.\n\nDuring the COVID-19 pandemic, some patients briefly fainted during nasal swab collection. This happens because inserting a swab into the back of the nasal cavity (nasopharynx) stimulates the trigeminal nerve, which then activates the vagus nerve and slows the heart - a phenomenon called the trigeminocardiac (or nasocardiac) reflex. One published case report described a patient whose SVT was terminated within 10 seconds using a nasal swab.\n\nThis study compares the nasal swab technique with the modified Valsalva maneuver in patients presenting to the emergency department with SVT. Patients are randomly assigned to one of two groups. The primary outcome is whether a normal heart rhythm is restored within 1 minute of the procedure. Patient comfort and satisfaction are also measured.\n\nThe study is conducted in two phases. The first (pilot) phase (30 patients per group) will assess whether the study can be successfully conducted and collect data to finalize the required sample size. The second (main) phase will use the pilot phase's actual data to determine the final number of participants needed.",[27,28,29,30],"Supraventricular Tachycardia","Paroxysmal Supraventricular Tachycardia","Atrioventricular Nodal Reentry Tachycardia","Vagal Maneuver",[32,33,34,35,36,37,38],"SVT","nasal swab","nasocardiac reflex","trigeminocardiac reflex","Valsalva maneuver","REVERT","emergency department","RECRUITING","2026-05-23",{"date":42,"type":43},"2026-06-01","ACTUAL",{"date":45,"type":43},"2026-05-01",{"date":47,"type":21},"2027-06",{"name":49,"class":50},"Marmara University Pendik Training and Research Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100497953","phase-2-the-node-202-study-study-of-etripamil-nasal-spray-in-pediatric-patients-100497953","NCT05763953","The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)","The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients With Paroxysmal Supraventricular Tachycardia","Inclusion Criteria:\n\nPatients will be eligible for study participation if they meet all of the following criteria at screening:\n\n1. Male or female patients\n\n   1. Part 1: patients 12 to \\\u003C18 years of age\n   2. Part 2: patients 6 to \\\u003C12 years of age\n2. Body mass index (BMI) between the 5th and the 85th percentiles interpreted relative sex and age\n3. History of PSVT documented by ECG or other monitoring modality (e.g., Holter monitor, event recorder) showing SVT involving the Atrioventricular (AV) node (i.e., Atrioventricular nodal reentry tachycardia (AVNRT) or Atrioventricular reentrant tachycardia (AVRT)). If patient had a prior ablation for PSVT, patient must have documented evidence of PSVT post-ablation\n4. Signed written informed consent\u002Fassent obtained\n5. Per Investigator's decision, females of childbearing potential (defined as any woman or adolescent who has begun menstruation) must additionally satisfy the following criteria:\n\n   1. Negative pregnancy test at screening\n   2. Adequate contraception, unless total abstinence is used\n6. Willing and able to comply with study procedures.\n\nExclusion Criteria:\n\nPatients will be excluded from the study if they meet any of the following criteria:\n\n1. History or presence of any of the following at the screening visit:\n\n   1. Patients with a history of atrial arrhythmia that does not involve the AV node as part of the tachycardia circuit (e.g., atrial fibrillation, atrial flutter, atrial tachycardia) are not eligible\n   2. Permanent junctional reciprocating tachycardia\n   3. Ventricular pre-excitation (e.g., delta wave on ECG, Wolff Parkinson White syndrome)\n   4. Second- or third-degree AV block\n   5. Sick sinus syndrome or clinically significant bradycardia (\\\u003C50 bpm or equivalent in this patient population) on the resting ECG\n   6. Ventricular tachycardia\n   7. Long QT syndrome\n   8. Major structural heart disease (e.g., Ebstein's anomaly, corrected congenital heart disease) or symptoms of congestive heart failure (New York Heart Association class II to IV).\n2. Evidence of impaired liver function (alanine aminotransferase \\[ALT\\] and\u002For aspartate aminotransferase \\[AST\\] \\>3 x upper limit of normal for age and gender) at the Screening Visit\n3. Evidence of End-Stage Renal Disease as determined by an estimated glomerular filtration rate assessed at the Screening Visit of \\\u003C15 mL\u002Fmin\u002F1.73m2, or requiring hemodialysis;\n4. Treatment with any of the following that cannot or will not be discontinued during study participation:\n\n   1. Any investigational drug within 60 days prior to study drug administration\n   2. IV beta-adrenergic blocking drugs (e.g., propranolol, esmolol), calcium channel blocking drugs (e.g., verapamil, diltiazem) or amiodarone within 24 hours prior to study drug administration\n   3. Oral amiodarone within 30 days prior to study drug administration\n   4. Class I or III antiarrhythmic agents (e.g., flecainide, propafenone, sotalol) within five half-lives prior to study drug administration\n   5. Any other drug that has a contraindication with verapamil\n5. Known hypersensitivity to verapamil or to any of the excipients of the study drug\n6. Any other significant co-morbid condition that may have a negative impact on the patient's participation in the study or likely to result in non-compliance\n7. History of hyperthyroidism\n8. Current pregnancy or breastfeeding","6 Years","17 Years",{"count":20,"type":21},[63],"PHASE2","NODE-202 is a Phase 2, multicenter, multinational, single dose, open-label, 2-part, sequential design study in pediatric patients with an established diagnosis of paroxysmal supraventricular tachycardia (PSVT) presenting with a symptomatic episode of PSVT.\n\nIn Part 1, at least 30 patients aged 12 to \\\u003C18 years will be enrolled and treated with etripamil nasal spray (NS). Efficacy, safety, tolerability and PK (for at least 12 patients) will be assessed after administration of 70 mg etripamil NS (Part 1A). At least 18 subsequent patients will be enrolled and treated with the etripamil NS with the dose determined by the Pharmacokinetic (PK) analysis and will undergo efficacy and safety\u002Ftolerability assessments (Part 1B).\n\nIn Part 2, at least 30 patients aged 6 to \\\u003C12 years will be enrolled and treated with etripamil NS at a dose selected based on appropriate body size-based modeling, as well as efficacy, safety\u002Ftolerability, and PK data collected in Part 1. Efficacy, safety, tolerability and PK (for at least 12 patients) will be assessed after administration of etripamil NS (Part 2A). At least 18 subsequent patients will be enrolled and treated with the etripamil NS with the dose determined by the PK analysis and will undergo efficacy and safety\u002Ftolerability assessments (Part 2B).\n\nThe study will include the following visits: A Screening Visit, A Treatment Visit, , and A Follow-Up\u002FEnd of Study Visit.",[28],[67],"PSVT","2025-07-31",{"date":70,"type":43},"2025-08-01",{"date":72,"type":43},"2023-12-11",{"date":74,"type":21},"2027-06-30",{"name":76,"class":50},"Milestone Pharmaceuticals Inc.",10,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":51},"100560185","outcomes-of-pfa-vs-rfa-for-patients-with-psvt-a-retrospective-and-propensity-score-matching-study-100560185","NCT06573853","Outcomes of PFA Vs. RFA for Patients with PSVT: a Retrospective and Propensity Score Matching Study","The Safety and Efficiency of Pulsed Field Ablation and Radiofrequency Ablation in the Treatment of Paroxysmal Supraventricular Tachycardia：a Retrospective and Propensity Score Matching Study","PFA*RFA*PSVT","Inclusion Criteria:\n\n1. Patients with symptomatic PSVT including: atrioventricular nodal re-entrant tachycardia (AVNRT), atrioventricular re-entrant tachycardia (AVRT);\n2. Age range: 18 years old ≤ age ≤ 80 years old, with no gender restriction;\n3. Willing to receive the examinations and testings during one year follow-up required by the protocol;\n4. Voluntary signed informed consent.\n\nExclusion Criteria:\n\n1. Organic heart disease;\n2. History of cardiac surgery;\n3. Previous failed ablation of PSVT;\n4. Presence of any implants, such as a permanent pacemaker;\n5. Patients with invasive systemic infections or advanced malignant tumors;\n6. Contraindications for septal puncture or retrograde transaortic access surgery;\n7. Any condition that makes the use of heparin or aspirin inappropriate;\n8. Pregnant or lactating women;\n9. Inability to fully comply with the study procedures and follow-ups or to provide their own informed consent;\n10. Coexistence with other arrhythmias, such as atrial fibrillation.","80 Years",{"count":88,"type":21},428,"OBSERVATIONAL","The goal of this retrospective study is to compare the long-term follow-up outcomes of pulses field ablation (PFA) Vs. radiofrequency ablation (RFA) for the patients with paroxysmal supraventricular tachycardia (PSVT). The main question to answer is:\n\nDoes the PFA was more effecient and safer that RFA for treatment of PSVT during procedure and after 1-year follow-up? Researchers will compare the acute and long-term efficiency and safety between PFA and RFA.\n\n1. Recieved PFA or RFA 1 year ago\n2. Finish the visit to the clinic at 1, 3, 6, 12 months for examinations and blood testings\n3. Patients recieved PFA and PFA under propensity matched comparison according to differen variety of PSVT",[28,92],"Catheter Ablation",[28,94,95],"Pulsed Field Ablation","Radiofrequency Ablation","2024-10-22",{"date":98,"type":43},"2024-10-24",{"date":100,"type":43},"2022-10-11",{"date":102,"type":21},"2025-06-30",{"name":104,"class":50},"Caijie Shen"]